# Coherex Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/coherex-medical

- Industry: Medical Devices & Equipment
- Headquarters: Salt Lake City, US
- Website: www.coherex.com
- Total disclosed funding: $25M
- Latest round: Series B (Aug 20, 2009)
- Investors on record: 3

## About

Coherex Medical Inc. specializes in developing innovative medical devices for diagnosing and treating heart rhythm disorders, notably targeting patients with atrial fibrillation through their advanced products.Founded in 2003, Coherex Medical Inc. is located in Salt Lake City, US, and focuses on creating medical solutions for heart conditions. The company was acquired by Biosense Webster, Inc. in November 2015, enhancing its strategic direction. The firm has participated in 4 deals, with the latest being a Series C funding round that raised USD 30.56 mn, bringing the total amount raised to USD 30.56 mn and currently valuing the company at USD 78.69 mn.Coherex Medical Inc. develops the WaveCrest® Left Atrial Appendage Occlusion (LAAO) System, designed to close the left atrial appendage to prevent stroke from blood clots in patients with atrial fibrillation. This product, currently in a U.S. Investigational Device Exemption (IDE) clinical trial, is specifically aimed at patients intolerant to long-term oral anticoagulation therapy and has received CE Mark approval for European markets.Revenue for Coherex Medical Inc. is primarily generated through the sale of its WaveCrest® System to hospitals and healthcare providers. The pricing of the device is often negotiated based on hospital procurement processes, ensuring that healthcare institutions access the technology they need while contributing to the company's financial stability.Coherex Medical Inc. aims to expand its product offerings by launching new medical devices focused on heart rhythm disorders, potentially in the upcoming years. The company plans to increase its market presence in North America and Europe, leveraging its recent funding of USD 30.56 mn from the Series C round to support these initiatives. This funding will be instrumental in enhancing clinical trials and facilitating market entry strategies for their products.

## Funding rounds

- Series B, Aug 20, 2009, $17M — Oxford Bioscience Partners, Tullis Health Investors, Signal Peak Ventures
- Series A, Apr 18, 2007, $8.5M — Oxford Bioscience Partners, Signal Peak Ventures

## Investors

- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series A, Series B
- Signal Peak Ventures (https://capitalatlas.ai/funds/signal-peak-ventures) — Series A, Series B
- Tullis Health Investors (https://capitalatlas.ai/funds/tullis-health-investors) — Series B